Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label, Phase I/Ib Study to Assess the Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

A Multi-center, Open-label, Phase I/Ib Study to Assess the Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RP 12146 (Primary)
  • Indications Advanced breast cancer; Biliary cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Male breast cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Rhizen Pharmaceuticals

    • Most Recent Events

    • 07 May 2024 Status changed from active, no longer recruiting to completed.
    • 02 Apr 2024 Planned End Date changed from 31 Mar 2024 to 30 Apr 2024.
    • 02 Apr 2024 Planned primary completion date changed from 1 Mar 2024 to 30 Apr 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top